Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.

Abstract

This article reviews current pharmacologic treatment options for 3 common men's health concerns: hypogonadism, erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). Specific topics addressed include: management of male hypogonadism using testosterone replacement therapy, use of oral phosphodiesterase inhibitors as first-line therapy for men with ED and the utility of intraurethral and intrapenile alprostadil injections for patients who do not respond to oral medications, and the role of alpha1-adrenergic antagonists, 5-alpha-reductase inhibitors, anticholinergic agents, and herbal therapies in the management of BPH.

• Authors: Kathryn E Berkseth, Arthi Thirumalai, John K Amory
• Journal: The Medical clinics of North America (Med Clin North Am) Vol. 100 Issue 4 Pg. 791-805 (Jul 2016) ISSN: 1557-9859 [Electronic] United States
• PMID: 27235615 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Inc. All rights reserved.

Chemical References

• 5-alpha Reductase Inhibitors
• Phosphodiesterase Inhibitors
• Testosterone

Topics

• 5-alpha Reductase Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Drug Administration Routes
• Drug Therapy, Combination
• Erectile Dysfunction (drug therapy)
• Humans
• Hypogonadism (drug therapy)
• Male
• Men's Health
• Phosphodiesterase Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Prostatic Hyperplasia (drug therapy)
• Testosterone (administration & dosage, adverse effects, therapeutic use)